Can a four-pronged attack shrink liver tumors enough for surgery?
NCT ID NCT07728019
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding an experimental drug called retlirafusp alfa to standard chemotherapy and bevacizumab, with or without a short course of radiotherapy, can shrink liver metastases from colorectal cancer enough to allow surgical removal. The study enrolls adults aged 18 to 75 with previously untreated colorectal cancer that has spread to the liver. The goal is to see if this combination improves progression-free survival and increases the chance of complete tumor removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- retlirafusp alfa combined with bevacizumab and chemotherapy, with or without short-course radiotherapy
- What this could lead to
- If successful, this combination could shrink liver metastases enough to allow surgical removal, potentially improving long-term outcomes for people with advanced colorectal cancer.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply broadly. Combining multiple treatments also raises the risk of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA WITH LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer?
- New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
- Real-World data on colorectal cancer: what happens to patients over time?
- New registry maps how targeted liver treatment is used in colorectal cancer
- Engineered immune cells take on Hard-to-Treat colorectal cancer
- New combo therapy aims to shrink liver tumors in hard-to-treat colorectal cancer